A Study of TeriQ Patch in Healthy Adult Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Osteoporosis
Interventions
DRUG

TeriQ Patch

"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"

DRUG

Teribone Inj.

"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"

DRUG

Forteo Inj.

"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"

Trial Locations (2)

6009

Linear Clinical Research Ltd., Nedlands

6027

Linear Clinical Research Ltd., Joondalup

All Listed Sponsors
lead

QuadMedicine

INDUSTRY

NCT06644040 - A Study of TeriQ Patch in Healthy Adult Female Participants | Biotech Hunter | Biotech Hunter